254 related articles for article (PubMed ID: 29348598)
1. Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy.
Hosoi A; Takeda K; Nagaoka K; Iino T; Matsushita H; Ueha S; Aoki S; Matsushima K; Kubo M; Morikawa T; Kitaura K; Suzuki R; Kakimi K
Sci Rep; 2018 Jan; 8(1):1058. PubMed ID: 29348598
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral CD8
Horton BL; Williams JB; Cabanov A; Spranger S; Gajewski TF
Cancer Immunol Res; 2018 Jan; 6(1):14-24. PubMed ID: 29097422
[TBL] [Abstract][Full Text] [Related]
3. TCR Repertoire Analysis Reveals Mobilization of Novel CD8
Aoki H; Ueha S; Shichino S; Ogiwara H; Hashimoto SI; Kakimi K; Ito S; Matsushima K
Front Immunol; 2018; 9():3185. PubMed ID: 30733724
[TBL] [Abstract][Full Text] [Related]
4. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
5. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
6. Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis.
Shitaoka K; Hamana H; Kishi H; Hayakawa Y; Kobayashi E; Sukegawa K; Piao X; Lyu F; Nagata T; Sugiyama D; Nishikawa H; Tanemura A; Katayama I; Murahashi M; Takamatsu Y; Tani K; Ozawa T; Muraguchi A
Cancer Immunol Res; 2018 Apr; 6(4):378-388. PubMed ID: 29475880
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
[TBL] [Abstract][Full Text] [Related]
8. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor Models.
Hekim C; Ilander M; Yan J; Michaud E; Smykla R; Vähä-Koskela M; Savola P; Tähtinen S; Saikko L; Hemminki A; Kovanen PE; Porkka K; Lee FY; Mustjoki S
Cancer Immunol Res; 2017 Feb; 5(2):157-169. PubMed ID: 28073775
[TBL] [Abstract][Full Text] [Related]
10. β-Adrenergic Signaling Impairs Antitumor CD8
Nissen MD; Sloan EK; Mattarollo SR
Cancer Immunol Res; 2018 Jan; 6(1):98-109. PubMed ID: 29146881
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
12. TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.
Shakiba M; Zumbo P; Espinosa-Carrasco G; Menocal L; Dündar F; Carson SE; Bruno EM; Sanchez-Rivera FJ; Lowe SW; Camara S; Koche RP; Reuter VP; Socci ND; Whitlock B; Tamzalit F; Huse M; Hellmann MD; Wells DK; Defranoux NA; Betel D; Philip M; Schietinger A
J Exp Med; 2022 Feb; 219(2):. PubMed ID: 34935874
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
14. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
15. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
Polesso F; Weinberg AD; Moran AE
Cancer Immunol Res; 2019 Feb; 7(2):269-281. PubMed ID: 30563828
[TBL] [Abstract][Full Text] [Related]
16. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
Marciscano AE; Ghasemzadeh A; Nirschl TR; Theodros D; Kochel CM; Francica BJ; Muroyama Y; Anders RA; Sharabi AB; Velarde E; Mao W; Chaudhary KR; Chaimowitz MG; Wong J; Selby MJ; Thudium KB; Korman AJ; Ulmert D; Thorek DLJ; DeWeese TL; Drake CG
Clin Cancer Res; 2018 Oct; 24(20):5058-5071. PubMed ID: 29898992
[No Abstract] [Full Text] [Related]
17. Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor.
Pasetto A; Gros A; Robbins PF; Deniger DC; Prickett TD; Matus-Nicodemos R; Douek DC; Howie B; Robins H; Parkhurst MR; Gartner J; Trebska-McGowan K; Crystal JS; Rosenberg SA
Cancer Immunol Res; 2016 Sep; 4(9):734-43. PubMed ID: 27354337
[TBL] [Abstract][Full Text] [Related]
18. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
19. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
20. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
